<DOC>
	<DOCNO>NCT00972075</DOCNO>
	<brief_summary>The aim placebo-controlled randomize study evaluate efficacy Circadin™ 2 mg improve total night sleep duration stabilize circadian clock phase totally blind subject non-24 hour sleep-wake disorder .</brief_summary>
	<brief_title>Efficacy Safety Circadin Non-24 Hour Sleep-Wake Disorder Totally Blind Subjects</brief_title>
	<detailed_description>This multi-center , double-blind , placebo-controlled study once-daily ( QD ) dose Circadin™ 2 mg subject non-24 hour sleep-wake disorder . Subjects initially treat placebo 2 week randomly assign 1:1 ratio receive Circadin™ 2 mg placebo 6 week , follow 2-week washout period . The primary objective ass effect Circadin 2 mg give daily 6 week total night sleep duration . Secondary objective sleep variable record diary like sleep latency , daytime nap sleep offset time . Other endpoint CGIC score Severity Illness Global Improvement WHO ( Five ) Well-Being Index score .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Blindness</mesh_term>
	<mesh_term>Sleep Wake Disorders</mesh_term>
	<mesh_term>Parasomnias</mesh_term>
	<mesh_term>Sleep Disorders , Circadian Rhythm</mesh_term>
	<mesh_term>Melatonin</mesh_term>
	<criteria>Male female subject age 2080 , conscious perception light . Meeting criterion diagnose Non24h cycle clinical setting : 1 ) difficulty initiate sleep difficulty awakening , 2 ) progressive delay sleep phase inability maintain entrainment 24hourday , 3 ) presence sleep pattern least six week . Average total night sleep duration le 6 hour per night least six week . Ability ingest oral medication participate schedule evaluation . Signing Informed Consent approve Ethics Committee . The Informed Consent write Braille blackandwhite form blind subject sight witness . Education work history sufficient exclude mental retardation . Stable medication nonexcluded concurrent medical condition four week prior screen visit . Presence medical disorder related blindness medical treatment may influence melatonin production , sleep alertness . To ascertained medical history , complete physical examination include ECG general biochemical workup include complete blood count , serum chemistry , urine analysis . Presence psychiatric mental disorder assess structured psychiatric interview perform trained individual . History seizure disorder . Irregular lifestyle life pattern ( e.g . shift worker patient unable keep study routine ) . Presence sleep problem reveal may explain subject ' complaint , sleep disorder breathing , restless leg syndrome periodic limb movement syndrome . Use benzodiazepines hypnotic study precede two week 5 half life whichever longer . Known suspect hypersensitivity exogenous melatonin melatonin receptor agonist Use melatonin precede two week Use psychiatric medication study precede three month . History autoimmune disease Pharmacological immunosuppression . Pregnancy lactation , childbearing potential lack adequate contraception . History severe pathology likely recur immediately study . Participation clinical trial investigational agent within two month prior study enrollment . Patients incapable perform daily call study IVRS system report questionnaire .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>totally blind subject</keyword>
</DOC>